Trial reportProgress in neuro-psychopharmacology & biological psychiatry2008
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
Trial report in Progress in neuro-psychopharmacology & biological psychiatry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05663749 (Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Does Adjuvant Metformin Reduce Olanzapine-Induced Metabolic Adverse Effects in Patients Diagnosed With Schizophrenia.Neuropsychopharmacology reports · 2025Pooled it
- Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.The Cochrane database of systematic reviews · 2021 · on this mapPooled it
- Vitamin D supplementation is effective for olanzapine-induced dyslipidemia.Frontiers in pharmacology · 2023Article
- Metformin Attenuates Liver Fat Content: Finding from Schizophrenia Patients with Olanzapine-induced Weight Gain.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2020Article
- Second generation antipsychotic-induced weight gain in youth with autism spectrum disorders: a brief review of mechanisms, monitoring practices, and indicated treatments.International journal of developmental disabilities · 2019Review
- Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes.Frontiers in neuroscience · 2017Review
- Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.Drugs · 2015 · on this mapReview
- Article
- Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia.Psychopharmacology · 2013Review
- Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?British journal of pharmacology · 2011Article
- Review
- Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management.Mens sana monographs · 2010Article
- Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.CNS drugs · 2009Review
- Metabolic risks in older adults receiving second-generation antipsychotic medication.Current psychiatry reports · 2009Review
- Post-graduate CME.Indian journal of psychiatry · 2008Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The second generation antipsychotic drugs, such as risperidone, olanzapine, and quetiapine, are effective in treating patients with schizophrenia and have been considered as the first line therapy. Recently, increasing attention has been drawn to the potential diabetogenic effect of these novel antipsychotics. The goal of this study was to evaluate the effect of metformin treatment on the olanzapine-induced metabolic disturbance in schizophrenic patients. Twenty-four schizophrenic subjects who had received olanzapine treatment at least 3 months were assigned to the therapy with metformin 1500 mg/day for 8 weeks. The metabolic parameters were quantitatively assessed at baseline, weeks 2, 4, and 8 by using the intravenous glucose tolerance test. After an 8-week treatment with metformin, the body weight, fasting levels of glucose, triglyceride, and insulin, insulin secretion, and insulin resistance significantly decreased. Half of study subjects with metabolic syndrome obtained improvement after the metformin trial. Subjects' psychopathological condition remained unchanged during the study period. The olanzapine-induced metabolic disturbance could be reversed after 8-week metformin treatment. Based on the results of this study, we hypothesize that metformin could modulate the effect of olanzapine-induced metabolic disturbance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.